Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation

Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation

Conditional marketing authorization (CMA) facilitates timely access to new drugs for illnesses with unmet clinical needs, such as late graft failure after kidney transplantation. Late graft failure remains a serious, burdensome, and life-threatening condition for recipients. This article has been de...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Naesens, M, Loupy, A, Hilbrands. L, Oberbauer, R, Bellini, MI, Glotz, D, Grinyó, J, Heemann, U, Jochmans, I, Pengel, L, Reinders, M, Schneeberger, S, Budde, K
Format:	Journal article
Sprog:	English
Udgivet:	Wiley 2022

Lignende værker

Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation
af: Roufosse, C, et al.
Udgivet: (2022)

Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation
af: Seron, D, et al.
Udgivet: (2022)

Allograft function as endpoint for clinical trials in kidney transplantation
af: Hilbrands, L, et al.
Udgivet: (2022)

Patient-reported outcomes as endpoints in clinical trials of kidney transplantation interventions
af: Tong, A, et al.
Udgivet: (2022)

Alloimmune risk stratification for kidney transplant rejection
af: Bestard, O, et al.
Udgivet: (2022)

Biomarkers and surrogate endpoints.
af: Aronson, J
Udgivet: (2005)

Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions
af: Aronson, J
Udgivet: (2008)

Trial design and end points in clinical transplant research
af: Knight, S, et al.
Udgivet: (2016)

Surrogate endpoints for neonatal outcome: A rapid review
af: Shiraz El Adam, et al.
Udgivet: (2024-08-01)

Quetiapine-Related Deaths: In Search of a Surrogate Endpoint
af: Ivan Šoša
Udgivet: (2024-01-01)

Significance of biomarkers and surrogate endpoints in preclinical and clinical trials
af: Ilić Katarina, et al.
Udgivet: (2007-01-01)

Surrogate endpoints in trials: a call for better reporting
af: Oriana Ciani, et al.
Udgivet: (2022-12-01)

Consensus statement on normothermic regional perfusion in donation after circulatory death: Report from the European Society for Organ Transplantation’s Transplant Learning Journey
af: Jochmans, I, et al.
Udgivet: (2021)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
af: Manyara, AM, et al.
Udgivet: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
af: Martin Offringa, et al.
Udgivet: (2022-10-01)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
af: Ciani, O, et al.
Udgivet: (2023)

Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study
af: Alexandre Loupy, et al.
Udgivet: (2021-10-01)

Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
af: Jeeyapant, A, et al.
Udgivet: (2017)

Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition
af: Gilbert Peter B., et al.
Udgivet: (2015-09-01)

Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients
af: J. R. Bank, et al.
Udgivet: (2015-01-01)

A call for better reporting of trials using surrogate primary endpoints
af: Anthony Muchai Manyara, et al.
Udgivet: (2022-01-01)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
af: Anthony Muchai Manyara, et al.
Udgivet: (2022-01-01)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
af: Behnood Bikdeli, et al.
Udgivet: (2017-03-01)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
af: Bishal Gyawali, et al.
Udgivet: (2020-04-01)

How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes
af: Bellini, MI, et al.
Udgivet: (2022)

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
af: Inker, LA, et al.
Udgivet: (2023)

Commentary on: A call for better reporting of trials using surrogate primary endpoints
af: Jeffrey Cummings
Udgivet: (2022-01-01)

Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
af: Wenbo Zhu, et al.
Udgivet: (2017-09-01)

Appropriate Surrogate Endpoint in Drug-Coated Balloon Trials for Coronary Artery Diseases
af: Xinyue Lang, et al.
Udgivet: (2022-06-01)

The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.
af: Bauke Schievink, et al.
Udgivet: (2014-01-01)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
af: Jianyang Liu, et al.
Udgivet: (2022-04-01)

Electrocardiogram in Friedreich's ataxia: A short‐term surrogate endpoint for treatment efficacy
af: Sandra Mastroianno, et al.
Udgivet: (2021-07-01)

Biomarkers and surrogate endpoints in the glaucomatous optic neuropathy: new developments and a review
af: Niro Kasahara
Udgivet: (2015-08-01)

Antidiabetic medications and mortality reduction: a shift from surrogate to clinical endpoints
af: Fariha Hasan, et al.
Udgivet: (2017-12-01)

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
af: Robert Kemp, et al.
Udgivet: (2017-07-01)

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
af: Charlotte Pawlyn, et al.
Udgivet: (2024-08-01)

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint
af: Duffy Stephen W, et al.
Udgivet: (2003-09-01)

European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study
af: Lucrezia Furian, et al.
Udgivet: (2024-04-01)

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.
af: Hugosson, J, et al.
Udgivet: (2001)

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
af: Lassere, M, et al.
Udgivet: (2007)